Zai Lab
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 49.0m | 144m | 215m | 267m | 396m | 591m | 929m |
| % growth | 277 % | 195 % | 49 % | 24 % | 49 % | 49 % | 57 % |
| EBITDA | (263m) | (703m) | (387m) | (360m) | (311m) | (213m) | (41.3m) |
| % EBITDA margin | (537 %) | (487 %) | (180 %) | (135 %) | (78 %) | (36 %) | (4 %) |
| Profit | (269m) | (704m) | (443m) | (335m) | (289m) | (168m) | 68.5m |
| % profit margin | (549 %) | (488 %) | (206 %) | (125 %) | (73 %) | (28 %) | 7 % |
| EV / revenue | 219.1x | 32.2x | 9.0x | 7.1x | 3.5x | 2.9x | 1.9x |
| EV / EBITDA | -40.8x | -6.6x | -5.0x | -5.3x | -4.5x | -8.0x | -41.9x |
| R&D budget | 223m | 573m | 286m | 266m | - | - | - |
| R&D % of revenue | 455 % | 397 % | 133 % | 100 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$30.0m | Series A | ||
N/A | Series A | ||
$100m | Series B | ||
$30.0m | Series C | ||
* | N/A | $115m | IPO |
| N/A | $140m | Post IPO Equity | |
| N/A | $215m | Post IPO Equity | |
| N/A | $281m | Post IPO Equity | |
| N/A | $761m | IPO | |
| N/A | $750m | Private Placement VC | |
| Total Funding | €827m | ||
Recent News about Zai Lab
EditZai Lab is a biopharmaceutical company focused on developing and commercializing innovative therapies for oncology, infectious diseases, and autoimmune disorders. The company serves patients with unmet medical needs, primarily in China and the Asia-Pacific region. Operating in the highly competitive biopharmaceutical market, Zai Lab collaborates with global partners to license and develop cutting-edge treatments. The business model revolves around research and development (R&D), clinical trials, and commercialization of novel drugs. Revenue is generated through product sales, licensing agreements, and strategic partnerships. Zai Lab's facilities in Suzhou, China, are designed to meet international standards, ensuring high-quality manufacturing of small molecule and biologic drugs.
Keywords: biopharmaceutical, oncology, infectious diseases, autoimmune disorders, R&D, clinical trials, commercialization, China, Asia-Pacific, innovative therapies.
